Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02559674
Title ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Altor Bioscience Corporation

pancreatic cancer


ALT-803 + Gemcitabine + Nab-paclitaxel

Age Groups: adult
Covered Countries USA

No variant requirements are available.